Abstract
Sweet’s syndrome (SS; acute febrile neutrophilic dermatosis) is a skin disorder characterized by acute tender erythematous plaques or nodules that may blister and ulcerate. The disease presents in several clinical settings including: classical (idiopathic) SS, malignancy-associated SS and drug-induced SS. Several drugs have been implicated in the etiopathogenesis of the disease with the most frequent being the granulocyte-colony stimulating factor. We report and discuss a case of SS associated with the intake of a selective cyclooxygenase-2 inhibitor, which has been rarely reported.